Advanced Prostate Cancer: Novel Agents from Annual Meeting, Sequencing and Combinations
Description: Daniel George, Director of the Prostate Clinic and the Director of GU Oncology at Duke Medicine, discusses the encouraging data presented at ASCO that will help change the way prostate and advanced prostate cancer is treated. Survival advantages are increasing as the new landscape of novel agents with different mechanisms of action are used in combination and in sequence. These novels agents include Radium 223, MDV3100 and currently approved Zytiga and Provenge. Dr. George also discusses the importance of having an individualized discussion with your healthcare team about how to increase survival benefits with different combinations and sequencing, while minimizing side effects to maintain the highest quality of life. This exciting news brings much hope for men with prostate cancer.
Shared By : patientpower
Posted on : 06/19/12
Added : 5 years ago